Alpha DaRT alpha-particle therapy, key 2026 trial catalysts, cash/dilution risks, and M&A takeover potential. See more.

A landmark UK trial aiming to revolutionise prostate cancer screening has begun testing its first male participants. The ...

Researchers have found a link between low testosterone levels and aggressive tumors, which could change how prostate cancer ...

Dementia is expected to proliferate along with the super elderly. So health practitioners are focused on screening for it.

This may not apply in your husband’s case, but it’s worth having the conversation. The two meds Goldstein prescribes for men ...

What if a medicine you thought of as “old news” suddenly showed up in new research with fresh benefits that might stretch ...

A non-ablative treatment for benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS) achieved durable ...

Pfizer is eyeing an earlier use of its PARP inhibitor Talzenna after a positive phase 3 trial in metastatic hormone-sensitive ...

Dr. Bertrand Tombal delivered a practical presentation titled “What Do You Need for Decision Making in mHSPC in 2026?”, ...

Tagawa, MD, identified 3 primary clinical scenarios where PSMA PET scans have become the established standard for prostate ...

Prostate-specific membrane androgen PET/CT can help clinicians intensify or de-escalate care for men with prostate cancer who ...

Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.